An Open-label, Single-dose Study of the Safety, Tolerability, and Pharmacokinetics of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency and Effect of Hemodialysis on AMG 423 Pharmacokinetics
Phase of Trial: Phase I
Latest Information Update: 12 Aug 2013
At a glance
- Drugs Omecamtiv mecarbil (Primary)
- Indications Heart failure
- Focus Pharmacokinetics
- 30 Apr 2013 During the first quarter of 2013, dosing was completed in part A of the trial according to a Cytokinetics media release.
- 05 Feb 2013 Dosing was initiated during the fourth quarter of 2012, according to a Cytokinetics media release.
- 07 Jan 2013 New trial record